| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
HMG-CoA reductase (HMGCR) is the rate-limiting enzyme in the cholesterol synthesis pathway. HMGCR inhibitors, statins, which are used to prevent cardiovascular diseases, have propensity to induce hyperglycemia. On the other hand, we showed that liver-specific HMGCR gene knockout (L-KO) mice exhibited low blood glucose and genes associated with hepatic glucose production were decreased in the liver. To investigate the role of HMGCR in the hepatic glucose production, we used the RNA-sequencing technology which can generate comprehensive transcriptomic information. We found out that one microRNA cluster in the liver of L-KO was induced and it may reduce the genes for hepatic glucose production.
|
